NZ Switch Committee Recommends OTC Access To AbbVie’s Maviret Hepatitis C Therapy

17 Aug 2023

New Zealand's Medicines Classification Committee has recommended expanded the dispensing conditions for AbbVie Inc.'s combination therapy for hepatitis C Maviret to include pharmacists who meet the requirements of the Pharmacy Council.

New Zealand On Map — • Source: Shutterstock

AbbVie Inc.'s combination therapy for hepatitis C, Maviret (glecaprevir/pibrentasvir), has been recommended for non-prescription use under certain conditions by New Zealand’s Medicines Classification Committee (MCC).

At its most recent meeting on 25 May, the MCC expanded the dispensing conditions for glecaprevir (100mg) in combination with...